eligibility_summary
Adults ≥18 with relapsed/refractory B‑cell cancers (FL, MCL, HCL, WM, BL, MZL, LBCL) meeting subtype‑specific prior‑therapy rules: e.g., FL POD24 or ≥2 lines incl anti‑CD20, MCL ≥2 incl anti‑CD20 or chemo+BTKi, WM ≥2 incl BTKi and chemo/PI with IgM ≥2×ULN, BL post frontline (no double/triple‑hit), MZL ≥2, HCL failed ≥2 incl purine analog. Need measurable disease or equivalent, CD22+, ECOG 0‑2, adequate organs. Exclude active infection/viremia, major CNS/cardiac disease, pregnancy, autoimmune on immunosuppression, other malignancy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT06340737 tests CD22CART: an autologous, genetically engineered CD22-directed CAR T-cell therapy (cellular gene therapy/adoptive cell transfer) given after lymphodepleting chemotherapy in adults with relapsed/refractory B‑cell lymphomas (FL, MCL, HCL, LPL/WM, BL, MZL, LBCL). Mechanism: patient T cells are modified to express a chimeric antigen receptor that binds CD22 on B cells, engagement activates T-cell signaling, proliferation, cytokine release, and perforin/granzyme-mediated cytolysis, leading to depletion of CD22+ malignant (and normal) B cells. Targets: CD22 (Siglec‑2) on mature B cells, an inhibitory coreceptor linked to B-cell receptor signaling, overall focuses on eradication of CD22-expressing B‑cell clones and disruption of malignant BCR-driven pathways. Primary outcomes: safety/efficacy (OS, PFS, DOR).